Literature DB >> 19156423

The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.

Mohsen Beheshti1, Sigrid Pöcher, Reza Vali, Peter Waldenberger, Gabriele Broinger, Michael Nader, Susanne Kohlfürst, Christian Pirich, Henning Dralle, Werner Langsteger.   

Abstract

The purpose of this prospective study was to compare the value of DOPA PET-CT with FDG PET-CT in the detection of malignant lesions in patients with medullary thyroid carcinoma (MTC). Twenty-six consecutive patients (10 men, 16 women, mean age 59 +/- 14 years) with elevated calcitonin levels were evaluated in this prospective study. DOPA and FDG PET-CT modalities were performed within a maximum of 4 weeks (median 7 days) in all patients. The data were evaluated on a patient- and lesion-based analysis. The final diagnosis of positive PET lesions was based on histopathological findings and/or imaging follow-up studies (i.e., DOPA and/or FDG PET-CT) for at least 6 months (range 6-24 months). In 21 (21/26) patients at least one malignant lesion was detected by DOPA PET, while only 15 (15/26) patients showed abnormal FDG uptake. DOPA PET provided important additional information in the follow-up assessment in seven (27%) patients which changed the therapeutic management. The patient-based analysis of our data demonstrated a sensitivity of 81% for DOPA PET versus 58% for FDG PET, respectively. In four (4/26) postoperative patients DOPA and FDG PET-CT studies were negative in spite of elevated serum calcitonin and CEA levels as well as abnormal pentagastrin tests. Overall 59 pathological lesions with abnormal tracer uptake were seen on DOPA and/or FDG PET studies. In the final diagnosis 53 lesions proved to be malignant. DOPA PET correctly detected 94% (50/53) of malignant lesions, whereas only 62% (33/53) of malignant lesions were detected with FDG PET. DOPA PET-CT showed superior results to FDG PET-CT in the preoperative and follow-up assessment of MTC patients. Therefore, we recommend DOPA PET-CT as a one-stop diagnostic procedure to provide both functional and morphological data in order to select those patients who may benefit from (re-)operation with curative intent as well as guiding further surgical procedures.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19156423     DOI: 10.1007/s00330-008-1280-7

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  48 in total

1.  Current approaches and perspectives in the therapy of medullary thyroid carcinoma.

Authors:  G Vitale; M Caraglia; A Ciccarelli; G Lupoli; A Abbruzzese; P Tagliaferri; G Lupoli
Journal:  Cancer       Date:  2001-05-01       Impact factor: 6.860

2.  Pentavalent Tc-99m DMSA scintigraphy. Prospective evaluation of its role in the management of patients with medullary carcinoma of the thyroid.

Authors:  O A Mojiminiyi; R Udelsman; N D Soper; B J Shepstone; N E Dudley
Journal:  Clin Nucl Med       Date:  1991-04       Impact factor: 7.794

Review 3.  The radionuclide molecular imaging and therapy of neuroendocrine tumors.

Authors:  Shuren Li; Mohsen Beheshti
Journal:  Curr Cancer Drug Targets       Date:  2005-03       Impact factor: 3.428

4.  Detection of medullary thyroid carcinoma and regional lymph node metastases by magnetic resonance imaging.

Authors:  Q Wang; S Takashima; H Fukuda; F Takayama; S Kobayashi; S Sone
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1999-08

5.  Potential role of fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) in the staging of primitive and recurrent medullary thyroid carcinoma.

Authors:  P Gasparoni; D Rubello; G Ferlin
Journal:  J Endocrinol Invest       Date:  1997-10       Impact factor: 4.256

6.  Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma.

Authors:  B Beuthien-Baumann; A Strumpf; J Zessin; J Bredow; J Kotzerke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-04-14       Impact factor: 9.236

7.  Comparison of imaging TNM [(i)TNM] and pathological TNM [pTNM] in staging of bronchogenic carcinoma.

Authors:  A Gdeedo; P Van Schil; B Corthouts; F Van Mieghem; J Van Meerbeeck; E Van Marck
Journal:  Eur J Cardiothorac Surg       Date:  1997-08       Impact factor: 4.191

8.  Somatostatin receptor scintigraphy for early detection of regional and distant metastases of medullary carcinoma of the thyroid.

Authors:  Y Krausz; A Rosler; H Guttmann; S Ish-Shalom; N Shibley; R Chisin; B Glaser
Journal:  Clin Nucl Med       Date:  1999-04       Impact factor: 7.794

9.  Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study.

Authors:  M Diehl; J H Risse; K Brandt-Mainz; M Dietlein; K H Bohuslavizki; P Matheja; H Lange; J Bredow; C Körber; F Grünwald
Journal:  Eur J Nucl Med       Date:  2001-11

10.  Interobserver variability and accuracy of computed tomographic assessment of nodal status in lung cancer.

Authors:  E C Bollen; R Goei; B E van 't Hof-Grootenboer; C W Versteege; H A Engelshove; R J Lamers
Journal:  Ann Thorac Surg       Date:  1994-07       Impact factor: 4.330

View more
  32 in total

1.  Evolving paradigms for successful molecular imaging of medullary thyroid carcinoma.

Authors:  Domenico Rubello; Ka Kit Wong; Maria Cristina Marzola; Mohsen Beheshti; Valentina Ambrosini; Sotirios Chondrogiannis; Milton D Gross
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-04       Impact factor: 9.236

2.  Clinical value of a combined multi-phase contrast enhanced DOPA-PET/CT in neuroendocrine tumours with emphasis on the diagnostic CT component.

Authors:  Patrick Veit-Haibach; Marc Schiesser; Jan Soyka; Klaus Strobel; Niklaus G Schaefer; Rolf Hesselmann; P-A Clavien; Thomas F Hany
Journal:  Eur Radiol       Date:  2010-08-15       Impact factor: 5.315

Review 3.  Radiopharmaceuticals as probes to characterize tumour tissue.

Authors:  Israt S Alam; Mubarik A Arshad; Quang-Dé Nguyen; Eric O Aboagye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-03       Impact factor: 9.236

4.  (68)Ga-somatostatin analogues PET and (18)F-DOPA PET in medullary thyroid carcinoma.

Authors:  Valentina Ambrosini; Maria Cristina Marzola; Domenico Rubello; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

Review 5.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

6.  Is there a role for fluorine-18 fluorodeoxyglucose positron emission tomography imaging in medullary thyroid cancer?

Authors:  Saila Kauhanen; Camilla Schalin-Jäntti
Journal:  Endocrine       Date:  2012-12       Impact factor: 3.633

7.  Dynamic risk stratification for medullary thyroid cancer according to the response to initial therapy.

Authors:  Hyemi Kwon; Won Gu Kim; Min Ji Jeon; Dong Eun Song; Yu-Mi Lee; Tae-Yon Sung; Ki-Wook Chung; Jong Ho Yoon; Suck Joon Hong; Jung Hwan Baek; Jeong Hyun Lee; Tae Yong Kim; Won Bae Kim; Young Kee Shong
Journal:  Endocrine       Date:  2016-01-11       Impact factor: 3.633

Review 8.  Advances in the follow-up of differentiated or medullary thyroid cancer.

Authors:  Rossella Elisei; Aldo Pinchera
Journal:  Nat Rev Endocrinol       Date:  2012-04-03       Impact factor: 43.330

9.  EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma.

Authors:  Luca Giovanella; Giorgio Treglia; Ioannis Iakovou; Jasna Mihailovic; Frederik A Verburg; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-04       Impact factor: 9.236

10.  [Oncologic imaging: indications for and limitations of modern cross-sectional imaging techniques].

Authors:  M E Mayerhoefer; A Ba-Ssalamah; H Prosch
Journal:  Radiologe       Date:  2013-04       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.